news
Medicare Weighs CGM Coverage for Non-Insulin Type 2 Diabetes
The New England Journal of Medicine published data from the CONNECT trial showing continuous glucose monitors significantly improve blood sugar control in non-insulin type 2 diabetes. The Centers for Medicare and Medicaid Services is now reviewing whether to expand coverage this year to millions of patients. If approved, the ruling shifts continuous metabolic tracking from an out-of-pocket luxury into standard primary care.
The New England Journal of Medicine published data from the CONNECT trial showing continuous glucose monitors significantly improve blood sugar control in non-insulin type 2 diabetes. The Centers for Medicare and Medicaid Services is now reviewing whether to expand coverage this year to millions of patients. If approved, the ruling shifts continuous metabolic tracking from an out-of-pocket luxury into standard primary care.
The architecture take
I used to think continuous glucose monitors on people who do not take insulin were mostly an expensive parlor trick for worried well tech founders. I was wrong about where the real leverage sits. When you actually see a bowl of oatmeal spike your blood sugar to 180 mg/dL twenty minutes after eating, your behavior changes faster than any physician lecture could ever manage. That real-time feedback loop calms postprandial glucose swings before they batter your vascular lining and exhaust your pancreatic beta cells. If Medicare approves coverage for non-insulin type 2 patients this year, Dexcom and Abbott will suddenly have access to an enormous patient population that private insurers will be forced to follow. I expect the ripple effect will dismantle the ridiculous boundary between medical diabetes management and proactive metabolic health. Watch private insurers fight the upfront hardware cost for six months before realizing that preventing one cardiovascular event pays for five years of sensors.